“Focused on the treatment of Alzheimer’s disease
and mild cognitive impairment.”
Actinogen Medical is a publicly listed (ASX: ACW) clinical-stage biotechnology company undertaking research in Alzheimer’s disease and other age-related neurodegenerative diseases.
Actinogen is developing a novel drug, Xanamem™, which has been specifically designed to block the production of cortisol in the brain.
Actinogen has successfully completed all the necessary early phase studies to confirm that Xanamem™ is well tolerated with an acceptable safety profile.
Actinogen is well advanced with plans to initiate a Phase II efficacy and safety study in mild Alzheimer’s disease patients in the second quarter of 2016. This study will be run in Australia, the United Kingdom, and the United States, under an FDA approved IND.
“Positive trial results confirm Xanamem™ is effectively delivered to the brain.”
– Dr. Bill Ketelbey, 29 September, 2015